InvestorsPrism
  • Home
  • Indexes
    • All Indexes
    • Cannabis
    • EV
    • Gene Therapy
    • MedDevices
    • MedDiagnostics
    • Solar
    • Uranium
    • Vaccines & Cell Therapy
    • Web 3.0
  • Companies
  • Trending News
    • Latest
    • Markets
    • Finance
    • Economy
    • Technology
    • Earnings
    • Healthcare
    • Prism Daily
  • Equity Research
    • Login
    • Register
    • User Profile
    • Log Out
  • Home
  • Indexes
    • All Indexes
    • Cannabis
    • EV
    • Gene Therapy
    • MedDevices
    • MedDiagnostics
    • Solar
    • Uranium
    • Vaccines & Cell Therapy
    • Web 3.0
  • Companies
  • Trending News
    • Latest
    • Markets
    • Finance
    • Economy
    • Technology
    • Earnings
    • Healthcare
    • Prism Daily
  • Equity Research
    • Login
    • Register
    • User Profile
    • Log Out

Home News Feeds Gene Therapy

Feed Category: Gene Therapy

February 06 at 4:00 pm

Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results

– Conference Call and Webcast Today, February 6, 2023 at 4:30 p.m. ETPASADENA, Calif., February 06, 2023–(BUSINESS WIRE)–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial… [Read More]
February 06 at 9:55 am

Wall Street Analysts Believe Intellia Therapeutics, Inc. (NTLA) Could Rally 145.32%: Here’s is How to Trade

Shares of Intellia Therapeutics, Inc. (NTLA) have gained 13.5% over the past four weeks to close the last trading session at $43.23, but there could… [Read More]
February 06 at 9:55 am

Wall Street Analysts Believe Fate Therapeutics (FATE) Could Rally 172.49%: Here’s is How to Trade

Shares of Fate Therapeutics (FATE) have gained 62% over the past four weeks to close the last trading session at $6.87, but there could still… [Read More]
February 06 at 9:35 am

2 High-Risk, High-Reward Stock Bets Cathie Wood Is Taking Into 2023

The tech-heavy Nasdaq represents a collection of more risky stocks than the other major indexes and that is reflected by a poorer performance in bear… [Read More]
February 06 at 8:15 am

Ready to Buy the Dip? Consider This Gene Editing Stock

With its share price off by 11% over the past 12 months, CRISPR Therapeutics (NASDAQ: CRSP) may be down, but it’s far from being out…. [Read More]
February 06 at 8:00 am

Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023

THOUSAND OAKS, Calif., February 06, 2023–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform… [Read More]
February 05 at 9:07 am

Even with Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stock down 7.7% this week, insiders who bought recently netted around US$70k

Insiders who bought Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stock lover the last 12 months are probably not as affected by last week’s 7.7% loss. Reason being,… [Read More]
February 04 at 9:40 am

3 No-Brainer Stocks to Buy Right Now for Less Than $25

In stock investing, it’s easy to focus on big names and blue-chip companies since they are frequently reported in financial media. Conversely, smaller companies, but… [Read More]
February 03 at 6:00 pm

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know

CRISPR Therapeutics AG (CRSP) closed at $55.27 in the latest trading session, marking a -1.51% move from the prior day. This move lagged the S&P… [Read More]
February 03 at 4:01 pm

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

THOUSAND OAKS, Calif., February 03, 2023–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform… [Read More]
February 03 at 2:43 pm

4 Biotech Stocks Set to Outpace Q4 Earnings Estimates

It has been an interesting earnings season for the Medical sector so far. The sector primarily comprises pharma/biotech and medical device companies.Several large drug and… [Read More]
February 03 at 12:10 pm

Why Editas Medicine’s Shares Jumped This Week

Shares of Editas Medicine (NASDAQ: EDIT) were up 21.1% for the week as of Friday morning, according to data provided by S&P Global Market Intelligence…. [Read More]

Posts navigation

Page 1 Page 2 … Page 9 Next page
InvestorsPrism

Copyright © 2023 Investors Prism
All rights reserved

Company

  • About Us
  • Contact Us
  • Privacy Policy
  • Disclaimer

News

  • Latest
  • Markets
  • Finance
  • Economy
  • Technology
  • Earnings
  • Healthcare
  • Prism Daily

Indexes

  • Cannabis
  • EV
  • Gene Therapy
  • MedDevices
  • MedDiagnostics
  • Solar
  • Uranium
  • Vaccines & Cell Therapy
  • Web 3.0